|
|
| | GDC-0810(ARN-810) Basic information |
| Product Name: | GDC-0810(ARN-810) | | Synonyms: | (E)-3-(4-((E)-2-(2-CHLORO-4-FLUOROPHENYL)-1-(1H-INDAZOL-5-YL)BUT-1-EN-1-YL)PHENYL)ACRYLIC ACID;GDC-0810(ARN-810);GDC-0810;(E)-3-[4-[(E)-2-(2-Chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl]phenyl]-2-propenoic acid;GDC-0810 (Brilanestrant);ARN-810;ARN-810;BRILANESTRANT;CS-2080 | | CAS: | 1365888-06-7 | | MF: | C26H20ClFN2O2 | | MW: | 446.9 | | EINECS: | | | Product Categories: | | | Mol File: | 1365888-06-7.mol |  |
| | GDC-0810(ARN-810) Chemical Properties |
| Boiling point | 622.8±55.0 °C(Predicted) | | density | 1.342±0.06 g/cm3(Predicted) | | solubility | DMSO:89.0(Max Conc. mg/mL);199.15(Max Conc. mM)
Ethanol:89.0(Max Conc. mg/mL);199.15(Max Conc. mM) | | form | A solid | | pka | 13.94±0.40(Predicted) | | color | White to off-white |
| | GDC-0810(ARN-810) Usage And Synthesis |
| Uses | Brilanestrant is an orally bioavailable Selective Estrogen Receptor Degrader (SERD) that demonstrates robust activity in tamoxifen-resistant breast cancer xenografts. GDC-0810 functions by binding to the estrogen receptor, inducing a conformational change resulting in the degradation of the receptor. GDC-0810 or ARN-810 demonstrates robust activity in models of tamoxifen-sensitive and tamoxifen-resistant breast cancer, and is currently in clinical trials in women with locally advanced or metastatic estrogen receptor-positive breast cancer. |
| | GDC-0810(ARN-810) Preparation Products And Raw materials |
|